Hua Li

Hua Li

Auto-generated profile, based on publicly available information

Hua Li

Nanoelectronics Laboratory, Department of Electrical Engineering and Computing Systems, University of Cincinnati, Cincinnati, Ohio 45221, USA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 August 2014 in Lab on a Chip
Verified
Journal Article
Closed access
PDF file
HLH. Li
H. Li
DHDaewoo Han
Daewoo Han
GPGiovanni M. Pauletti
Giovanni M. Pauletti
ASA. J. Steckl
A. J. Steckl
A simple approach to the evaluation of blood coagulation using a microfluidic paper-based lateral flow assay (LFA) device for point-of-care (POC) and self-monitoring screening is reported. The device utilizes whole blood, without the need for prior separation of plasma from red blood cells (RBC). Experiments were performed using animal (rabbit) blood treated with trisodium citrate to prevent coagulation. CaCl2 solutions of varying concentrations are added to citrated blood, producing Ca2+ ions to re-establish the coagulation cascade and mimic different blood coagulation abilities in vitro. Blood samples are dispensed into a paper-based LFA device consisting of sample pad, analytical membrane and wicking pad. The porous nature of the cellulose membrane separates the aqueous plasma component from the large blood cells. Since the viscosity of blood changes with its coagulation ability, the distance RBCs travel in the membrane in a given time can be related to the blood clotting time. The distance of the RBC front is found to decrease linearly with increasing CaCl2 concentration, with a travel rate decreasing from 3.25 mm min−1 for no added CaCl2 to 2.2 mm min−1 for 500 mM solution. Compared to conventional plasma clotting analyzers, the LFA device is much simpler and it provides a significantly larger linear range of measurement. Using the red colour of RBCs as a visible marker, this approach can be utilized to produce a simple and clear indicator of whether the blood condition is within the appropriate range for the patient's condition.

1 March 2017 in Biomicrofluidics
Verified
Journal Article
Closed access
PDF file
HLH. Li
H. Li
DHDaewoo Han
Daewoo Han
MHM. A. Hegener
M. A. Hegener
GPGiovanni M. Pauletti
Giovanni M. Pauletti
ASA. J. Steckl
A. J. Steckl
The “no reaction” lateral flow assay (nrLFA) uses a simplified LFA structure with no conjugate pad and no stored reagents. In the nrLFA, the capillary-based transport time or distance is the key indicator, rather than the outcome of a biochemical reaction. Hence, the calibration and reproducibility of the nrLFA device are critical. The capillary flow properties of several membrane types (nitrocellulose, nylon, cellulose acetate, polyethersulfone, and polyvinylidene difluoride) are evaluated. Flow rate evaluations of MilliporeSigma Hi-Flow™ Plus (HF075, HF135 and HF180) nitrocellulose membranes on nrLFA are performed using bodily fluids (whole blood, blood plasma, and artificial sweat). The results demonstrate that fluids with lower viscosity travel faster, and membranes with slower flow rate exhibit higher capability to distinguish fluids with different viscosities. Reproducibility tests of nrLFA are performed on HF075, demonstrating excellent reproducibility. The coefficient of variation for blood coagulation tests performed with the nrLFA using induced coagulation was 5% for the plasma front and 2% for the RBC front. The effects of variation in blood hematocrit and sample volume are also reported. The overall results indicate that the nrLFA approach has a high potential to be commercially developed as a blood monitoring point-of-care device with simple calibration capability and excellent reproducibility.

10 July 2017 in Biomedical Microdevices
Verified
Journal Article
Closed access
PDF file
MHMichael A. Hegener
Michael A. Hegener
HLHua Li
Hua Li
DHDaewoo Han
Daewoo Han
ASAndrew J. Steckl
Andrew J. Steckl
GPGiovanni M. Pauletti
Giovanni M. Pauletti

1 August 2020 in Translational Pediatrics
Verified
Journal Article
Open access
PDF file
HLHua Li
Hua Li
MOMei Ouyang
Mei Ouyang
PZPeiqi Zhang
Peiqi Zhang
LFLingxia Fei
Lingxia Fei
XHXiangshu Hu
Xiangshu Hu
Background: The ketogenic diet (KD) has been implemented in many different counties. However, in China, study concerning the efficacy of the KD is still at an early-stage of evaluation. Furthermore, the KD is thought to be incompatible with Chinese children because of its lack of palatability, especially for the Asian population. In addition, its substantial antiepileptic effect remains to be confirmed. Methods: To evaluate the efficacy and safety of the KD treatment of refractory childhood epilepsy in China, we prospectively enrolled 147 children with refractory epilepsy for KD treatment in Guangdong 999 Brain Hospital and followed up the children for 6 months. Outcome was measured by seizure frequencies before and after the KD diet and adverse effects. We also evaluated influences of different variables (starting age, duration of epilepsy, and others) on the outcome. Results: We found after 1 month, 3 months, and 6 months of KD treatment, 28.0%, 55%, and 67.9% of the subjects remained on diet with a >50% seizure reduction and seizure-free rates of 6.5%, 13.2%, and 23.3%, respectively. Gender, starting age, duration, etiology, classification, and seizure type of epilepsy showed no significant influence on efficacy. Anorexia, diarrhea, and gravel were the main side-effects of the KD treatment. Conclusions: In conclusion, the KD is a safe and efficacious method for childhood refractory epilepsy treatment.

17 May 2018 in Analytical Methods
Verified
Journal Article
Closed access
PDF file
HLHua Li
Hua Li
DHDaewoo Han
Daewoo Han
GPGiovanni M. Pauletti
Giovanni M. Pauletti
MHMichael A. Hegener
Michael A. Hegener
ASAndrew J. Steckl
Andrew J. Steckl
A simple method to correct the effect of hematocrit (Hct) on a paper-based lateral flow assay device that is designed to assess whole blood coagulation is reported.

1 May 2021 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
XZXin Zheng
Xin Zheng
HGHuitao Gao
Huitao Gao
YZYanbao Zhang
Yanbao Zhang
XCXinge Cui
Xinge Cui
RJRanran Jia
Ranran Jia
HWHongyun Wang
Hongyun Wang